Core Viewpoint - The company BaiO Saite-B (02135) has signed a licensing agreement with German ADC developer Tubulis, leveraging its RenMice fully human antibody development platform for innovative ADC therapies, which is expected to enhance its market position and revenue potential [1] Group 1: Licensing Agreement with Tubulis - On September 16, BaiO Saite announced a licensing agreement with Tubulis to utilize its RenMice platform for developing ADC therapies, which includes an upfront payment and milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1] - The stock price of BaiO Saite increased by over 7% in the afternoon trading session, reflecting positive market sentiment regarding the agreement [1] Group 2: Previous Agreement with Merck - On September 4, BaiO Saite signed an antibody option and evaluation agreement with Merck to assess the fully human antibodies developed using the RenMice platform for potential applications in nucleic acid drug delivery [1] - The agreements with Tubulis and Merck highlight the international competitiveness and drug conversion potential of BaiO Saite's fully human antibody platform, as stated by the company's Chairman and CEO Shen Yuelai [1]
百奥赛图-B午后涨超7% 再与Tubulis达成许可交易 公司月初与默克达成合作